



Controlled hyperventilation using a new ventilation navigator software: a feasibility study to provoke hypocapnia and respiratory alkalosis

A proposal for coronary artery vasoreactivity assessment

Attila Kardos ^{1,2,*}, Qi Yong ³, Barbara Kardos ^{1,2}, Nerea Sanfeliu Garces ^{1,2}, Ellie Burgess ^{1,2}, Kenneth Chan ⁴, and Nikolaos Makris ⁵

¹Department of Cardiology, Translational Cardiovascular Research Group, Milton Keynes University Hospital NHS Foundation Trust, 8H Standing Way, Eaglestone, Milton Keynes MK6 5LD, UK

²Faculty of Medicine and Health Sciences, University of Buckingham, Buckingham, UK

³Faculty of Engineering and Applied Sciences, Cranfield University, Cranfield, UK

⁴Division of Cardiovascular Medicine, Acute Multidisciplinary Imaging & Interventional Centre, British Heart Foundation Centre of Research Excellence, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

⁵Department of Critical Care, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK

Received 20 January 2026; accepted after revision 10 April 2026; online publish-ahead-of-print 17 April 2026

Abstract

Aims

To develop a ventilation navigator to provide controlled hyperventilation and to assess the feasibility to monitor hypocapnia and respiratory alkalosis in healthy subjects.

Methods and results

We developed the Ventilation Navigator software using C++ and utilizing high-precision timers as an advanced platform for respiratory guidance and control, incorporating adjustable breathing rate, and tidal volume, a session timer for automatic cessation. Its graphical user interface is designed to deliver clear visual cues to the patient, facilitating controlled breathing. We assessed the utility of controlled hyperventilation in five healthy probands using end-tidal CO₂ (ETCO₂) against capillary CO₂ and pH. We have successfully achieved respiratory alkalosis (pH >7.50) between 70% and 90% of the subjects' baseline ETCO₂. The linear mixed-effects modelling demonstrated a significant association between ETCO₂ and capillary pH ($\beta = -0.063$, SE = 0.008, $P < 0.001$). There was a moderate, clinically relevant agreement between capillary and ETCO₂ with an offset of 0.48 (1.50 - (-0.54)); however, ETCO₂ was significantly associated with capillary CO₂ ($\beta = 0.737$, SE = 0.115, $P < 0.001$) after accounting for repeated measures within individuals. A strong within-individual associations for ETCO₂ vs. capillary CO₂ as demonstrated (R_{rm} = 0.857, 95% confidence interval: 0.628–0.949, $P < 0.001$).

Conclusion

We developed a ventilation navigator application to deliver a controlled hyperventilation and assess its feasibility to monitor hypocapnia and respiratory alkalosis in healthy subjects. We are proposing this controlled physiological test to be implemented in the routine diagnostic workup to investigate coronary vasoreactivity in patients having angina with non-occlusive coronary artery disease after it has been validated in patients.

* Corresponding author. E-mail: attila.kardos@cardiov.ox.ac.uk


© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Lay summary

In this study, we developed a respiration navigator software to govern patients breathing. We know that over-breathing can cause chest pain (angina) in patient with no blockages in their heart arteries because of the heart artery spasm. Our described controlled breathing technique, which we validated against capillary blood gas (blood CO₂ and pH level) could provide a non-invasive tool to assess patients with angina and no blockages in their heart arteries.

Graphical Abstract



RWMA, regional wall motion abnormality; INOCA, ischaemia with non-occlusive coronary artery disease; ANOCA, angina with non-occlusive coronary artery disease; CFVR, coronary flow velocity reserve; VSA, vasospastic angina; CMD, coronary microvascular disease; MPSE, multi-parametric stress echocardiography; HPE, hyperventilation provocation echocardiography.

Keywords

ventilation navigator • hyperventilation test • vasoreactivity • ANOCA

Introduction

Chest pain is a common reason for primary care visit worldwide, accounting for about 1–2% of all consultations,^{1–3} approximately 5.6% of all emergency department visits in the USA annually⁴ and approximately 0.5% of outpatient clinic visits.⁵ Some of the patients will have occlusive coronary artery disease (CAD) to explain their symptoms; however, others who suffer from angina may have non-occlusive CAD (defined as no or <50% stenosis of the epicardial coronary arteries) termed as ANOCA. It is

estimated that approximately 30–50% of males and 50–70% of females with chest pain have ANOCA. The pathophysiology has been widely investigated but far from fully established. It is believed that ANOCA is caused by coronary microvascular disease (CMD) and/or epicardial or microvascular coronary vasoreactivity, and often in combination.⁶

The current established methods, such as stress Positron Emitting Tomography (PET) perfusion images,^{7,8} stress perfusion cardiac magnetic resonance imaging (MRI),^{9,10} and stress echocardiography with Doppler coronary flow measurement,




Figure 1 Feasibility of the ventilation navigator guided hyperventilation. Comparison of ET_{CO}₂ with capillary blood gas analysis. (A) Ventilation Navigator—to govern respiration rate, tidal volume (details in the [Methods](#)). (B) Blood gas monitor device for capillary pH, and CO₂. (C) Hyperventilating healthy proband with the capnograph showing respiration rate of 21 breath/min that resulted an ET_{CO}₂ of 2.8 kPa corresponding with a capillary pH of 7.56 indicative of significant respiratory alkalosis necessary for provoking smooth muscle vasospasm of the coronary arteries if susceptible.

are the non-invasive ways to assess CMD based on myocardial or coronary flow reserve.^{11,12} However, ANOCA endotypes also include abnormal vasoreactivity of the epicardial or microvascular coronary circulation.^{6,13,14} These non-invasive tests cannot provide this information. Invasive functional coronary physiological testing (IFCA) is able to provide with the currently proposed endotypes for ANOCA patients to facilitate personalized management, although at a risk associated with invasive coronary angiography and wire manipulation in the coronary arteries during the test^{15,16} Albeit IFCA is not suitable for repeated testing to investigate therapeutic response in ANOCA patients.

Hyperventilation and cold pressor tests had been proposed as non-pharmacological and non-invasive physiological interventions to assess coronary vasoreactivity.^{17,18} Of these two tests, hyperventilation is deemed to be the more feasible, reproducible, and patient-friendly test. This causes respiratory alkalosis and sympathetic stimulation, which alters intracellular calcium handling and subsequent vasospasm as a mechanism.


In this paper, we are addressing the need for a precise, reproducible hyperventilation test. We developed a ventilation navigator application to deliver a controlled (tidal volume and respiratory rate modulated) hyperventilation and assessed its feasibility in healthy subjects during hypocapnia and related respiratory alkalosis, which in turn can be implemented to

investigate coronary vasoreactivity in ANOCA patients once validated.

Methods and protocol

Ventilation navigator application

We have developed a software application that is able to govern patients' ventilation frequency and tidal volume using a visual scale on a computer monitor ([Figure 1](#) and [Video 1](#)). The Ventilation Navigator software serves as an advanced platform for respiratory guidance and control, incorporating a comprehensive range of features such as adjustable breathing rate, and tidal volume, a session timer for automatic cessation, and customizable breathing pattern settings. Its graphical user interface is purposefully designed to deliver clear and engaging visual cues to the patient, facilitating precise regulation of respiratory movements whilst minimizing distractions and cognitive demand. Developed in C++ (C++23, New Jersey, USA) and utilizing high-precision timers, the software ensures optimal accuracy and reliability for clinical applications. The Ventilation Navigator can be used to adjust respiratory parameters to achieve controlled hyperventilation in turn to accomplish respiratory alkalosis sufficient to provoke vasospasm of the pre-arterioles/arterioles or capillaries level similar to the effect of acetylcholine intracoronary injection.



Video 1 Ventilation navigator to govern respiration rate and tidal volume (details in the [Methods](#)). The Ventilation Navigator application was developed as an advanced platform for respiratory guidance with adjustable respiration rate and tidal volume. The session timer for automatic cessation of the task. Its graphical user interface is designed to deliver clear and engaging visual cues to the patient.

Feasibility of the end-tidal CO₂ (ETCO₂) during controlled hyperventilation against capillary pH and CO₂ in healthy subjects

We use ETCO₂ monitoring via a Dual Nasal Cannula (3 m O₂/CO₂ Pk 25) as an indicator of hypocapnia as a gauge to assess the effect of controlled hyperventilation on blood pH. The ETCO₂, representing the partial pressure of carbon dioxide at the end of exhalation (range 4.0–5.7 kPa as normocapnia). We validated the ETCO₂ (using Qube Mini, 92516 Capnography Pod, Spacelab Healthcare, USA) against the capillary CO₂ and capillary pH (Blood Gas analyser, ABL90 Flex Plus, UK) in five healthy volunteers (four female and one male age range 24–45 years). The healthy probands underwent controlled hyperventilation at different respiratory frequencies with fixed (non-quantified) tidal volume (by following the excursion [amplitude] of the up and down moving column on the visual scale

during controlled breathing) for 3 min at each respiration rate to achieve the 90%, 80%, 70%, and 60% of their individual baseline ETCO₂ calculated prior the test. The capillary blood gas was evaluated with a finger-prick from the non-dominant fingers at the end of each 3-min period for capillary CO₂ and pH, whilst constantly monitoring the vital signs (heart rate, O₂ saturation, ETCO₂) and symptoms. The respiratory rates were adjusted on the Ventilation Navigator application on a PC for each volunteer, to visually follow the wide up-and-down moving column to navigate respiration. The effect of controlled hyperventilation on the capillary CO₂ and capillary pH and ETCO₂ in the individual healthy probands are listed in [Table 1](#). The calibration related to the blood gas analyser has been provided in [Supplementary data online, Figure S1](#).

Statistical analysis

Continuous variables were expressed as mean and 95% confidence intervals as all data were normally distributed (Shapiro–Wilk test). The parameters of the calculated ETCO₂ subgroups (BL-90–80–70–60%) as a function of controlled hyperventilation were compared using Student's *t*-test. The relationships between two variables (ETCO₂ and capillary CO₂ or capillary pH) were analysed using repeated measures of correlation (Rmc), and expressed as coefficients of repeated measurements (Rrm). The degree of agreement between capillary CO₂ and ETCO₂ were analysed with Bland–Altman method corrected to repeated measures for individual data points of the probands and as aggregate average for each proband. Statistical significance was defined as *P* < 0.05. MedCalc Version 23.4.5 (MedCalc Software Ltd, Mariakerke, Belgium) and R test R environment (R 4.5.3, The R Foundation for Statistical Computing, <http://www.R-project.org>) with Rmcorr package for repeated measures correlation and lme4 package for mixed linear model was used for analyses.

The study was carried out according to the principles of the Declaration of Helsinki and in compliance with Good Clinical Practice.

Results

The calculated targeted ETCO₂ derived from the individual baseline ETCO₂ was closely achieved during controlled hyperventilation (calculated: 90–80–70% were achieved: 86–77–65% during hyperventilation). Each proband reached respiratory alkalosis defined as capillary pH ≥ 7.5. Three of the five probands reached pH ≥ 7.5 at the 90% of their baseline ETCO₂ with minimal change in their respiratory rate ([Tables 1 and 2](#)). The difference in the measured variables during spontaneous breathing and with Ventilation Navigator–controlled breathing—was due to the controlled fixed tidal volume as a possible explanation. In one of the cases respiratory alkalosis was only achieved at the respiratory rate of 27 at the 70% value of the baseline ETCO₂ (2.7 kPa). The case 5 had only two measurements at baseline and at 80% of her baseline ETCO₂ due to the required calibration error of the blood gas analyser that resulted in termination of her test. Two of the subjects had symptoms related to respiratory alkalosis of mild headache and palmar numbness at 60% of baseline ETCO₂ (2.5 kPa) and light-headedness at 90% of ETCO₂ (3.4 kPa). The others had no symptoms.

Relationship between ETCO₂ vs. capillary pH and capillary CO₂ vs. capillary pH

Responsiveness analysis showed good association between capillary pH and ETCO₂ or capillary CO₂ ([Figure 2](#)). Linear mixed-effects modelling demonstrated that ETCO₂ was

Table 1 Controlled ventilation and changes in capillary blood gas and ETCO₂ parameters in healthy probands

Stages	Respiratory rate	ETCO ₂	Capillary CO ₂	Capillary pH	Symptoms
Case 1 (f, 24)					
Base line ETCO ₂	8	4.2	4.25	7.439	No
90%	15	3.6	2.65	7.55	No
80%	17	3.3	3.15	7.554	No
70%	21	2.8	3.13	7.56	No
60%	26	2.5	3.05	7.557	Palmar numbness, headache
Case 2 (f, 42)					
Base line ETCO ₂	8	4.7	4.63	7.495	No
90%	9	3.4	3.5	7.591	Lightheaded
80%	10	3	3.52	7.58	Lightheaded
70%	10	2.6	2.76	7.66	Lightheaded
Case 3 (m, 32)					
Base line ETCO ₂	17	4.2	4.83	7.471	No
90%	8	3.7	4.11	7.517	No
80%	10	3.3	3.66	7.559	No
70%	19	2.9	3.61	7.562	No
60%	25	3	3.44	7.575	No
Case 4 (f, 36)					
Base line ETCO ₂	10	4.3	5.26	7.459	No
90%	13	3.9	4.83	7.484	No
80%	22	3.2	4.65	7.498	No
70%	27	2.7	4.23	7.53	No
Case 5 (f, 40)					
Base line ETCO ₂	22	4.4	5.16	7.415	No
80%	14	3.52	4.57	7.459	No

Respiratory rate (breath/min), ETCO₂ (kPa), capillary CO₂ (kPa). M (): male (age), f (): female (age).

Table 2 Summary table of controlled ventilation and changes in blood gas and ETCO₂ parameters in healthy probands

Stages (n)	Respiratory rate (bpm)	ETCO ₂ (kPa)	Capillary CO ₂ (kPa)	Capillary pH
All				
Base line (5)	13 (5.2–20.8)	4.3 (4.1–4.6)	4.8 (4.3–5.3)	7.45 (7.42–7.49)
90% (4)	11 (6.0–16.5)	3.7 (3.3–4.0)*	3.8 (2.3–5.2)*	7.54 (7.46–7.59)*
80% (5)	15 (8.2–20.1)	3.3 (3.0–3.5)*#	3.9 (3.1–4.7)*	7.53 (7.47–7.59)*
70% (4)	19 (8.0–30.4)	2.8 (2.5–3.0)*#	3.4 (2.4–4.4)*	7.58 (7.49–7.67)*#
60% (2)	26 (19.1–31.9)	2.8 (–0.43–5.9)	3.2 (0.8–5.7)*	7.57 (7.45–7.68)*

Values are mean (95% confidence interval). Note all data were normally distributed (Shapiro–Wilk test).

RR: $P > 0.05$ NS. Paired t test. ETCO₂: $P < 0.05$ *BL, #90%, \$80%. Capillary CO₂: $P < 0.05$ *BL. Capillary pH: $P < 0.05$ *BL, #90%.

bpm, breath per minute; kPa, kilo Pascal.

significantly associated with capillary pH after accounting for repeated measures within individuals ($\beta = -0.063$, SE = 0.008, $P < 0.001$). Significant association between capillary pH and capillary CO₂ was also observed ($\beta = -0.079$, SE = 0.005, $P < 0.001$). Random slope models did not improve fit, supporting a common within-subject relationship. Similarly, for every 1-unit increase in capillary CO₂, capillary pH decreased by approximately 0.079 units, after accounting for repeated measurements within subjects (Figure 2, Supplementary data online, Figure S2).

We found a strong within-individual associations for both capillary pH vs. ETCO₂ as well as capillary pH vs. capillary CO₂, as

demonstrated by high R_{rm} value and statistical significance. Regression lines between individual are mostly parallel with no outliers in slopes, suggesting good fit of the repeated measure correlation model (Figure 2).

Relationship between ETCO₂ and capillary CO₂

Bland–Altman analysis corrected for repeat measurements analysis showed a moderate, clinically relevant agreement between capillary CO₂ and ETCO₂ with an offset of 0.48 (1.50 – (–0.54))




Figure 2 Relationship between ETCO_2 vs. capillary pH and capillary CO_2 vs. capillary pH. Responsiveness analysis shows good association between capillary pH and ET-CO_2 or capillary CO_2 (A, B). Respiratory alkalosis defined as capillary pH >7.5 was achieved at different respiratory frequencies and corresponded to the ETCO_2 of <3.5 kPa. Linear mixed-effects modelling between ETCO_2 vs. capillary pH, (C) and Capillary CO_2 vs. capillary pH (D). ETCO_2 was significantly associated with capillary pH ($\beta = -0.063$, $\text{SE} = 0.008$, $P < 0.001$), after accounting for repeated measures within individuals. Note the high R_{rm} value and statistical significance as a sign of the strong within individual associations for both capillary pH vs. ETCO_2 as well as capillary pH vs. capillary CO_2 . Regression lines between individual are mostly parallel with no outliers in slopes, suggesting good fit of the repeated measure correlation model.

for individual data points of the probands and aggregate average for each proband (Figure 3).

Linear mixed-effects modelling between ETCO_2 vs. capillary CO_2 showed that ETCO_2 was significantly associated with capillary CO_2 ($\beta = 0.737$, $\text{SE} = 0.115$, $P < 0.001$), after accounting for repeated measures within individuals. For every 1-unit increase in ETCO_2 capillary CO_2 increased by approximately 0.74 units, after accounting for repeated measurements within subjects. A strong within individual associations for both ETCO_2 vs. capillary CO_2 as demonstrated by high R_{rm} value and statistical significance. Regression lines between individual are mostly parallel with no outliers in slopes, suggesting good fit of the repeated measure correlation model (Figure 3). For every 1-unit increase in ETCO_2 , capillary CO_2 increased by ~ 0.74 units, after accounting for repeated measurements within subjects.

Discussion

To be able to develop an entirely non-invasive, echocardiography-based pathway to help to determine ANOCA endotypes we have developed a Ventilation Navigator software to aid to deliver controlled hyperventilation. Hyperventilation provocation test is a well-established modality to elicit coronary vasospasm due to respiratory alkalosis and consequential calcium ion overload of the smooth muscle cells at the pre-arterioles, arterioles and capillary level.^{17,18,19,20} Using the controlled hyperventilation we found a

moderate, clinically relevant agreement between ETCO_2 and capillary CO_2 with an offset of 0.48 kPa. Nevertheless, respiratory alkalosis, defined as blood pH ≥ 7.5 , could be achieved between 90% and 70% of the baseline ETCO_2 of individuals with the help of the Ventilation Navigator that is not dependent on excessive increase of the respiratory rate, once the tidal volume is standardized. Moreover, ETCO_2 was significantly associated with capillary pH, which makes it an important marker for clinical monitoring of respiratory alkalosis during controlled hyperventilation.

Proposed clinical translation of the findings

With our feasibility data, we would like to propose the implementation of the controlled hyperventilation-based echocardiography (HPE) to investigate patients with suspected ANOCA in the multi-parametric stress echocardiography (MPSE) protocol as a hypothetical pathway. Of course, our controlled hyperventilation protocol would need to be validated in prospective patients with suspected coronary vasoreactivity before widespread clinical implementation.

The controlled HPE can provide with a non-invasive assessment of epicardial and microvascular coronary vasoreactivity by monitoring patients' symptoms, ST segments changes on 12-lead ECG (≥ 1 mm ST depression or elevation in 2 neighbouring leads), and left ventricular wall thickening using contrast-enhanced echocardiography (Figure 3) during hyperventilation-induced




Figure 3 Relationship between ETCO₂ and capillary CO₂. Bland-Altman analysis corrected for repeat measurements analysis showed a moderate, clinically relevant agreement between capillary and ETCO₂ with an offset of 0.48 (1.50 – (–0.54)) for individual data points of the probands (A) and aggregate average for each proband (B). Linear mixed-effects modelling between ETCO₂ vs. capillary CO₂. (C) ETCO₂ was significantly associated with capillary CO₂ ($\beta = 0.737$, SE = 0.115, $P < 0.001$), after accounting for repeated measures within individuals strong within individual associations for both ETCO₂ vs. capillary CO₂ as demonstrated by high R_{rm} value and statistical significance. Regression lines between individual are mostly parallel with no outliers in slopes, suggesting good fit of the repeated measure correlation model.

respiratory alkalosis. In addition to symptoms and ST changes on ECG, echocardiographic assessment of inducible ischaemia has improved the diagnostic accuracy from 60% to 91% during hyperventilation.¹⁷

Hyperventilation-provocation echocardiography showed a specificity of 100%, a sensitivity of 84%, a positive predictive value of 100%, and a negative predictive value of 92% in a patient with chest pain.²¹ Hyperventilation test has a Class IIa recommendation by the Japanese Society of Cardiology guidelines for diagnosing VSA.¹⁸

Since its diagnostic accuracy, HPE combined with MPSE, as a fully non-invasive pathway, can also be used as a triaging tool to select patients who need further testing by IFCA. Figure 4 offers a conceptual overview of the diagnostic pathway for suspected ANOCA, based on MPSE to assess CMD and HPE to address vasoreactivity and the relevant endotypes to guide personalized management. ANOCA patients with no inducible ischaemia with normal CFVR and negative vasoreactivity testing should be considered for IFCA as a confirmatory investigation especially if symptoms and cardiovascular risk factors for ANOCA are convincing.

Pathophysiology of ANOCA

Disease of the coronary macro- and microcirculation can develop due to structural or functional changes. The structural abnormality entails diffuse or focal atherosclerosis, intimal thickening, smooth muscle cell thickening or proliferation, perivascular fibrosis/inflammation, capillary obstruction or reduced capillary diameter or density (aka rarefaction). Functional anomalies can be abnormal vasoconstriction, impaired vasodilatation, endothelial dysfunction.²² Twenty-five percent of patients with ANOCA had inducible ischaemia, 50% have CMD because of abnormal endothelium independent vasodilatation, 60% have epicardial or microvascular vasoreactivity (6).

Diagnostic modalities in assessing ANOCA

To be able to address appropriate therapy in such patients, the mechanism must be identified, however challenging it is. Based on IFCA, three different endotypes of ANOCA have been described: CMD, epicardial vasospastic angina, and microvascular vasospastic angina. Beyond the three main endotypes, there are four different overlap endotypes as a combination of two

cold-pressor test would provide similar vasospastic stimulus; however, its execution is more difficult and less tolerated by patients.^{19,20}

Once the HPE has been validated exclusion criteria would be defined and provided, for patients in whom hyperventilation can adversely affect their underlying medical conditions and could put patients at risk of serious adverse reaction. Patients in whom hyperventilation provocation would cause safety concerns are those with severe pulmonary disease (such as severe asthma, chronic obstructive pulmonary disease, interstitial lung disease), recent cerebrovascular disease (TIA, stroke, intracranial haemorrhage), or known cerebral artery aneurysm, or sustained ventricular arrhythmia.

Conclusion

We assessed the feasibility of controlled hyperventilation using Ventilation Navigator application, with good agreement and correlation between ETCO_2 and capillary blood gas values. We found that by monitoring ETCO_2 and controlling respiration rate, respiratory alkalosis can safely be reached as a provocation test for vasoreactivity. We propose controlled hyperventilation provocation test as a complimentary test to identify vasoreactivity forms of ANOCA endotypes. MPSE in combination with HPE can diagnose CMD and endothelium dependent coronary vasospasm in ANOCA patients. The seven distinct endotypes of ANOCA can be identified to deliver targeted therapy for symptomatic control, to avoid recurrent hospital admissions, monitor therapy and reduce healthcare costs. Of course prior clinical implementation this pathway will have to be proven valid in ANOCA/INOCA patients ([Graphical Abstract](#)).

Supplementary data

Supplementary data are available at [European Heart Journal - Imaging Methods and Practice](#) online.

Consent

Institutional Review Board Statement: "The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (AUD-226 January 2022)." All participants as staff members of the cardiology department gave their verbal consent.

Funding

No funding was received for this work.

Conflict of interest: None declared.

Data availability

Data used in this study can be available from the corresponding author at reasonable request.

Lead author biography



Professor Attila Kardos is a consultant cardiologist in Milton Keynes University Hospital, where he is also the Associate Director of Research and the Director of the Translational Cardiovascular Research Group that is affiliated to University of Buckingham. He has a Honorary Chair at the University of Buckingham as Professor of Cardiovascular Medicine, and holds a Visiting Professorial position at both Cranfield and Open Universities. He is an

Honorary Senior Lecturer to the Division of Cardiovascular Medicine at the Radcliffe Department of Medicine, University of Oxford. He is the director of the Multimodality Cardiovascular Imaging Services in Milton Keynes. He has over 25 years of research experience and 32 years of clinical experience of which the last 23 years as a consultant.

Professor Kardos is a chief investigator in several research trials and projects. His research interest expands to cardiovascular imaging modalities (CCTA and stress echocardiography) pathophysiology of stable and acute coronary syndromes in particular ANOCA, AI algorithm in cardiovascular diagnostics, and predictive modelling, AI and Robotics in cardiovascular imaging. He has published over 125 peer-reviewed journal articles, H-index: 24; He has been invited as well as Keynote speaker at National and International Conferences >120. He has supervised 5 MSc, DPhil/PhD/MD students Professor Kardos is a Fellow of the RCP and the European Society of Cardiology and a member of several International Societies such as EACVI, SCCT, BCS, AHA, ACC, ASE etc.). Associate Editor of *Frontiers in Cardiovascular Medicine*, *Journal of Clinical Medicine*, *Cardiovascular Endocrinology & Metabolism*, and reviewer to several Journals e.g. *The Lancet*, *Open Heart*, *Open BMJ*, *JMIR*, *Frontiers in Cardiovascular Medicine*.

References

1. Cairns C, Kang K. *National Hospital Ambulatory Medical Care Survey: 2021 Emergency Department Summary Tables*. 2021 [internet publication]. 1–248.
2. Centers for Disease Control and Prevention. *National Center for Health Statistics: Survey Results and Products—2019 National Ambulatory Medical Care Survey Summary Tables*. 2023.
3. Ruigómez A, Rodríguez LA, Wallander MA, Johansson S, Jones R. Chest pain in general practice: incidence, comorbidity and mortality. *Fam Pract* 2006;**23**: 167–74.
4. Walters K, Rait G, Hardoon S, Kalaitzaki E, Petersen I, Nazareth I. Socio-demographic variation in chest pain incidence and subsequent coronary heart disease in primary care in the United Kingdom. *Eur J Prev Cardiol* 2014; **21**:566–75.
5. Ruigómez A, Massó-González EL, Johansson S, Wallander MA, García-Rodríguez LA. Chest pain without established ischaemic heart disease in primary care patients: associated comorbidities and mortality. *Br J Gen Pract* 2009;**59**:e78–86.
6. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J. 2024 ESC Guidelines for the management of chronic coronary syndromes: developed by

- the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) *Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)*. *Eur Heart J* 2024;**45**:3415–537.
7. Schindler TH, Fearon WF, Pelletier-Galarneau M, Ambrosio G, Sechtem U, Ruddy TD et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction: a JACC: cardiovascular imaging expert panel statement. *JACC Cardiovasc Imaging* 2023;**16**:536–48.
 8. Ismayl M, Raphael CE, Prasad A, Chareonthaitawee P, Bois JP. Agreement of Doppler flow velocity reserve with PET flow reserve in patients with angina without obstructive coronary arteries. *Mayo Clin Proc* 2024;**99**:2005–7.
 9. Sharrack N, Chiribiri A, Schwitter J, Plein S. How to do quantitative myocardial perfusion cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging* 2022;**23**:315–8.
 10. Engblom H, Xue H, Akil S, Carlsson M, Hindorf C, Oddstig J et al. Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. *J Cardiovasc Magn Reson* 2016;**19**:78.
 11. Carbone A, D'Andrea A, Sperlongano S, Tagliamonte E, Mandoli GE, Santoro C et al. Echocardiographic assessment of coronary microvascular dysfunction: basic concepts, technical aspects, and clinical settings. *Echocardiography* 2021;**38**:993–1001.
 12. Ciampi Q, Zagatina A, Cortigiani L, Gaibazzi N, Borguezan Daros C, Zhuravskaya N et al. Functional, anatomical, and prognostic correlates of coronary flow velocity reserve during stress echocardiography. *J Am Coll Cardiol* 2019;**74**:2278–91.
 13. Ciampi Q, Zagatina A, Cortigiani L, Gaibazzi N, Borguezan Daros C et al. Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA* 2014;**312**:1754–63.
 14. Tavella R, Cutri N, Tucker G, Adams R, Spertus J, Beltrame JF. Natural history of patients with insignificant coronary artery disease. *Eur Heart J Qual Care Clin Outcomes* 2016;**2**:117–24.
 15. Demir OM, Boerhout CK, de Waard GA, van de Hoef TP, Patel N, Beijk MA et al. Comparison of Doppler flow velocity and thermodilution derived indexes of coronary physiology. *JACC Cardiovasc Interv* 2022;**15**:1060–70.
 16. Perera D, Berry C, Hoole SP, Sinha A, Rahman H, Morris PD et al. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership. *Heart* 2023;**109**:88–95.
 17. Hirano Y, Ozasa Y, Yamamoto T, Uehara H. Hyperventilation and cold-pressor stress echocardiography for noninvasive diagnosis of coronary artery spasm. *J Am Soc Echocardiogr* 2001;**14**:626–33.
 18. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina). *Circ J* 2014;**78**:2779–801.
 19. Yamamoto T, Hirano Y, Ozasa Y, Uehara H, Sasaki T, Ishikawa K. Hyperventilation cold pressor stress echocardiography for diagnosis of vasospastic angina. *J Noninvas Cardiol* 1998;**6**:14–20.
 20. Wojta J. Vascular smooth muscle cells: regulation of vasoconstriction and vasodilation. In: Geiger M, ed. *Fundamentals of Vascular Biology*. Learning Materials in Biosciences. Cham: Springer; 2024.XXVII, p528.
 21. Morales MA, Reisenhofer B, Rovai D, Moscarelli E, Distanti A, L'Abbate A. Hyperventilation-echocardiography test for the diagnosis of myocardial ischaemia at rest. *Eur Heart J* 1993;**14**:1088–93.
 22. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. *J Am Coll Cardiol* 2018;**72**:2625–41.
 23. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *J Am Coll Cardiol* 2021;**78**:2218–61.
 24. Montone RA, Rinaldi R, Del Buono MG, Gurgoglione F, La Vecchia G, Russo M et al. Safety and prognostic relevance of acetylcholine testing in patients with stable myocardial ischaemia or myocardial infarction and non-obstructive coronary arteries. *Eur Intervent* 2022;**18**:e666–76.
 25. Zavorsky GS, Cao J, Mayo NE, Gabbay R, Murias JM. Arterial versus capillary blood gases: a meta-analysis. *Respir Physiol Neurobiol*. 2007;**155**:268–79.